Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Pulmatrix (NASDAQ: PULM) Investor Presentation
Newsmakers
CytoDyn (OTC: CYDY) to Deliver Presentation at Biotech Showcase Conference
BLA update and major licensing initiatives in cancer and immunology VANCOUVER, Washington, Jan 08, 2019- CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that […]
Healthcare
CytoDyn (OTC: CYDY) Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
VANCOUVER, Washington, Aug. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]
CEO Interview
CytoDyn, Inc. (OTC: CYDY) “Game Changer” HIV treatment nears commercialization (plus high-potential cancer drug pipeline)
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest […]